Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05717400 · ClinicalTrials.gov registry record · Phase 4
Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy
A Phase 4 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 4
- Development phase
- 2
- Enrollment target
NCT05717400: Clinical Trial Phase 4 study, sponsored by M.D. Anderson Cancer Center.
NCT05717400 is a Phase 4 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 2 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05717400, a Phase 4 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 2 participants
- Enrollment target
Study Summary
To learn if giving immune checkpoint therapy (such as atezolizumab) and bevacizumab to patients who have HCC and are receiving DAAs may help to control HCC and hepatitis C.
Primary Outcome
Stable Disease in 2 out of 2 patients
Interventions
- DRUG Bevacizumab
- DRUG Atezolizumab
- DRUG Sofosbuvir
- DRUG Velpatasvir
- DRUG Voxilaprevir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2023-03-17 |
| Est. Completion | 2024-08-29 |
| Phase | Phase 4 |
Why NCT05717400 stopped before completion
NCT05717400 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 5 interventions - of which Bevacizumab is the first listed.
NCT05717400 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05717400 about?
NCT05717400 is a clinical study titled "Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy". To learn if giving immune checkpoint therapy (such as atezolizumab) and bevacizumab to patients who have HCC and are receiving DAAs may help to control HCC and hepatitis C.
What is the current status of trial NCT05717400?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 2 participants. The study started on 2023-03-17. Estimated completion is 2024-08-29.
What interventions are being tested in trial NCT05717400?
The interventions under investigation include: Bevacizumab (DRUG), Atezolizumab (DRUG), Sofosbuvir (DRUG), Velpatasvir (DRUG), Voxilaprevir (DRUG).
Who is sponsoring clinical trial NCT05717400?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05717400's enrollment target sits among peer trials
2 1998th of 2000 higher than 1 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI